Razmpoosh Elham, Sivanandy Mala S, Ehrlich Alan M
Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON L8S 4L8, Canada.
PCOS Center, Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Biomedicines. 2025 Jan 13;13(1):177. doi: 10.3390/biomedicines13010177.
/: This systematic review and meta-analysis aimed to investigate the effect of prebiotics, alone or as part of synbiotics, on cardiometabolic parameters in polycystic ovary syndrome (PCOS) women. : Databases, including PubMed, Scopus, ISI Web of Science, Embase, and the Cochrane Central Register of Controlled Trials, were searched for relevant randomized-controlled trials (RCTs) until 12 December 2024. Changes in mean ± standard deviations were extracted and combined using a random-effects model. Bias was assessed using Cochrane risk of bias and evidence quality with GRADE. : Twenty RCTs with 1271 participants were included. Results showed high-quality evidence supporting prebiotics' effects, alone or as part of synbiotics, in reducing body-mass index [ = 853; weighted-mean difference (WMD): -0.510, 95%CI: -0.669, -0.351 kg/m] and diastolic blood pressure (WMD: -2.218, 95%CI: -4.425, -0.010 mmHg), moderate-quality evidence for weight, waist-to-hip ratio, and triglycerides improvements, and low or very-low-quality evidence for waist circumference (WC), fat mass, fasting plasma glucose, fasting insulin, low-density lipoprotein (LDL), total cholesterol (TC), high sensitive-C reactive protein, total testosterone, follicle-stimulating hormone and free androgen index improvements. Subgroup analyses revealed possible reduction in LDL with prebiotics, as well as possible decreases in WC, TC, and total testosterone with synbiotics. Dietary approaches to stop hypertension diet improved insulin sensitivity. : This study suggests that prebiotics may beneficially affect several cardiometabolic parameters in PCOS women. Approximately one-third of the results were based on moderate-to-high-quality evidence. This study highlights the need for future well-designed, larger RCTs with longer treatment duration to strengthen the evidence base and guide clinical decision-making.
本系统评价和荟萃分析旨在研究益生元单独使用或作为合生元的一部分,对多囊卵巢综合征(PCOS)女性心脏代谢参数的影响。检索了包括PubMed、Scopus、ISI科学网、Embase和Cochrane对照试验中央注册库在内的数据库,以查找相关的随机对照试验(RCT),检索截至2024年12月12日。提取平均±标准差的变化,并使用随机效应模型进行合并。使用Cochrane偏倚风险评估偏倚,并采用GRADE评估证据质量。纳入了20项随机对照试验,共1271名参与者。结果显示,有高质量证据支持益生元单独使用或作为合生元的一部分,在降低体重指数[ = 853;加权平均差(WMD):-0.510,95%置信区间:-0.669,-0.351 kg/m²]和舒张压(WMD:-2.218,95%置信区间:-4.425,-0.010 mmHg)方面的效果;有中等质量证据支持在改善体重、腰臀比和甘油三酯方面的效果;有低或极低质量证据支持在改善腰围(WC)、脂肪量、空腹血糖、空腹胰岛素、低密度脂蛋白(LDL)、总胆固醇(TC)、高敏C反应蛋白、总睾酮、促卵泡生成素和游离雄激素指数方面的效果。亚组分析显示,益生元可能降低LDL,合生元可能降低WC、TC和总睾酮。采用终止高血压饮食的饮食方法可改善胰岛素敏感性。本研究表明,益生元可能对PCOS女性的多个心脏代谢参数产生有益影响。大约三分之一的结果基于中高质量证据。本研究强调,未来需要设计良好、规模更大、治疗持续时间更长的随机对照试验,以加强证据基础并指导临床决策。